The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure

Basit Öğe Kaydı
dc.contributor.authorGurgun, Cemil
dc.contributor.authorIldizli, Muege
dc.contributor.authorYavuzgil, Oguz
dc.contributor.authorSin, Aytuel
dc.contributor.authorApaydin, Anil
dc.contributor.authorCinar, Cahide
dc.contributor.authorKultursay, Hakan
dc.date.accessioned2019-10-27T19:55:49Z
dc.date.available2019-10-27T19:55:49Z
dc.date.issued2008
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: Statins may provide additional benefits in patients with cardiac failure due to their pleiotropic effects besides their cholesterol-lowering actions. In this study, we aimed to evaluate the impact of 12-week fluvastatin therapy on the inflammatory cytokines and the ventricular performance markers in patients with heart failure. Methods and results: Fourty chronic heart failure patients, twenty with idiopathic dilated cardiomyopathy (DCM group) and 20 with ischemic cardiomyopathy (ICM group), for whom statin treatment was indicated according to Adult Treatment Panel III were included to this open label and prospective study. After a 12-week treatment with fluvastatin 80 mg/day; clinical functional capacity, echocardiographic indices of cardiac performance and inflammatory markers were evaluated. After the treatment, functional capacity (in DCM group: 2.05 +/- 0.4 versus 1.65 +/- 0.6, p = 0.005; in ICM group: 2.25 +/- 0.5 versus 1.8 +/- 0.6, p= 0.003), left ventricular ejection fraction, LVEF (from 30 +/- 5% to 33 +/- 5%, p= 0.001 in DCM and 29 +/- 4% to 31 +/- 5%, p= 0.001 in ICM group) and tissue Doppler mitral annular systolic velocity, Sm (5.8 +/- 1 cm/s to 7 +/- 1 cm/s, p= 0.001 in DCM and 5.4 +/- 0.8 cm/s to 7 +/- 1 cm/s, p= 0.001 in ICM group) improved. Tumor necrosis factor-alpha and interleukin-6 levels decreased, but no significant changes in high sensitive C-reactive protein and brain natriuretic peptide levels were detected with the fluvastatin treatment in both groups. Conclusion: Fluvastatin improved cardiac functions and the clinical symptoms in HF patients with either idiopathic dilated or ischemic etiology. This positive effect of fluvastatin which might be secondary to inflammatory modulation was more marked in patients with ischemic etiology. Statins in HF deserves special attention by means of further large-scale trials. (c) 2007 Elsevier Ireland Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.ijcard.2006.11.152en_US
dc.identifier.endpage107en_US
dc.identifier.issn0167-5273
dc.identifier.issn1874-1754
dc.identifier.issue2en_US
dc.identifier.pmid17320212en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage102en_US
dc.identifier.urihttps://doi.org/10.1016/j.ijcard.2006.11.152
dc.identifier.urihttps://hdl.handle.net/11454/40736
dc.identifier.volume123en_US
dc.identifier.wosWOS:000252154900006en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Ireland Ltden_US
dc.relation.ispartofInternational Journal of Cardiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectheart failureen_US
dc.subjectstatinsen_US
dc.subjectinflammationen_US
dc.titleThe effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failureen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu